FrancophonIA/ELRC3.0 huggingface dataset:
English: Before preparation of infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller Formula)
Estonian: Enne infusioonilahuse valmistamist tuleb arvutada patsiendi kehapinna suurus (BSA), kasutades järgmist valemit: (Mostelleri valem)
English: 35 mg for moderate hepatic impairment (from one 70 mg vial)
Estonian: 35 mg keskmise raskusega maksakahjustuse korral (ühest 70 mg viaalist)
English: • Chills
Estonian: • hingeldus;
English: INSTRUCTIONS FOR USE IN PAEDIATRIC PATIENTS (Caspofungin Accord 70 mg)
Estonian: KASUTAMISJUHEND TÄISKASVANUD PATSIENTIDEL (Caspofungin Accord 70 mg)
English: What Caspofungin Accord is used for
Estonian: Milleks Caspofungin Accord'i kasutatakse
English: How to store Caspofungin Accord
Estonian: Kuidas Caspofungin Accord'i säilitada
English: An initial 70 mg loading dose should be administered on Day-1.
Estonian: Esimesel ravipäeval manustatakse 70 mg algannus.
English: Close monitoring of liver enzymes should be considered if the two medicinal products are used concomitantly.
Estonian: Nimetatud ravimite samaaegsel kasutamisel tuleb hoolikalt jälgida maksaensüümide aktiivsust.
English: c. Caspofungin Accord is formulated to provide the full labeled vial dose (50 mg) when 10 mL is withdrawn from the vial.
Estonian: c. Caspofungin Accord'i kogu viaali sildil märgitud annuse (50 mg) saab siis, kui viaalist eemaldada 10 ml.
English: Visually inspect the infusion solution for particulate matter or discolouration.
Estonian: Infusioonilahust tuleb visuaalselt kontrollida sademe või värvuse muutuse suhtes.
English: the caspofungin plasma AUC0-24 hr was generally comparable to that seen in adults receiving caspofungin at 50 mg daily.
Estonian: 70 mg ööpäevas), oli kaspofungiini plasma AUC0-24hr üldiselt võrreldav 50 mg ööpäevas kaspofungiini saanud täiskasvanutega.
English: Two hundred twenty-four patients were included in the primary efficacy analysis (MITT analysis) of response at the end of IV study therapy; favourable response rates for the treatment of invasive candidiasis were comparable for caspofungin (73 % [80/109]) and amphotericin B (62 % [71/115]) [% difference 12.7 (95.6 % CI -0.7, 26.0)].
Estonian: Invasiivse kandidiaasi ravi efektiivsus oli kaspofungiini (73% [80/109]) ja amfoteritsiin B (62% [71/115]) grupis võrreldav [erinevus 12,7% (95,6%, CI -0,7; 26,0)].
English: • Belly pain, upper belly pain, bloating, constipation, difficulty swallowing, dry mouth, indigestion, passing gas, stomach discomfort, swelling due to build-up of fluid around the belly
Estonian: • kõhuvalu, ülakõhuvalu, kõhupuhitus, kõhukinnisus, neelamisraskus, suukuivus, seedehäire, kõhugaasid, ebamugavustunne maos, turse vedeliku kogunemisest kõhupiirkonda;
English: Forty-nine patients were enrolled and received caspofungin at 50 mg/m2 IV once daily following a 70-mg/m2 loading dose on
Estonian: Uuringusse kaasati 49 patsienti, kes said kaspofungiini annuses 50 mg/m2 i.v.
English: 35 mg for moderate hepatic impairment (from one 50 mg vial)
Estonian: 35 mg keskmise raskusega maksakahjustuse korral (ühest 50 mg viaalist)
English: If you get any side effects, talk to your doctor or pharmacist.
Estonian: Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti, meditsiiniõe või apteekriga.
English: c. Caspofungin Accord is formulated to provide the full labelled vial dose (70 mg) when 10 mL is withdrawn from the vial.
Estonian: c. Caspofungin Accord'i kogu viaali sildil märgitud annuse (70 mg) saab siis, kui viaalist eemaldada
English: General disorders and administration site conditions pyrexia, chills, infusion-site pruritus pain, catheter site pain, fatigue, feeling cold, feeling hot, infusion site erythema, infusion site induration, infusion site pain, infusion site swelling, injection site phlebitis, oedema peripheral, tenderness, chest discomfort, chest pain, face oedema, feeling of body temperature change, induration, infusion site extravasation, infusion site irritation, infusion site phlebitis, infusion site rash, infusion site urticaria, injection site erythema, injection site oedema, injection site pain, injection site swelling, malaise, oedema
Estonian: veenipõletik süstekohas, perifeersed tursed, valulikkus, ebamugavustunne rindkeres, rindkerevalu, näo turse, kehatemperatuuri muutuse tunne, induratsioon, ekstravasatsioon infusioonikohas, infusioonikoha ärritus, veenipõletik infusioonikohas, lööve infusioonikohas, nõgestõbi infusioonikohas, süstekoha punetus, süstekoha turse, süstekoha valu, süstekoha paistetus, halb enesetunne, tursed
English: Skin and subcutaneous tissue disorders rash, pruritus, erythema, hyperhidrosis erythema multiforme, rash macular, rash maculo-papular, rash pruritic, urticaria, dermatitis allergic, pruritus generalised, rash erythematous, rash generalised, rash morbilliform, skin lesion
Estonian: Naha ja nahaaluskoe kahjustused lööve, kihelus, erüteem, liighigistamine multiformne erüteem, makuloosne lööve, makulopapuloosne lööve, kihelev lööve, urtikaaria, allergiline dermatiit, generaliseerunud kihelus, erütematoosne lööve, generaliseerunud lööve, morbilliformne lööve, nahakahjustus toksiline epidermise nekrolüüs ja Stevensi-Johnsoni sündroom (vt lõik 4.4)
English: Laboratory abnormalities in liver function tests have been seen in healthy volunteers and adult and paediatric patients treated with caspofungin.
Estonian: Kaspofungiiniga ravitud tervetel vabatahtlikel, lastel ja täiskasvanud patsientidel on täheldatud normist kõrvalekaldeid maksafunktsiooni laboratoorsete analüüside tulemustes.
English: The following adverse reactions were reported:
Estonian: Kõrvaltoimete loetelu tabelina Kirjeldati järgimisi kõrvaltoimeid:
English: Metabolism and nutrition disorders hypokalemia fluid overload, hypomagnesaemia, anorexia, electrolyte imbalance, hyperglycaemia, hypocalcaemia, metabolic acidosis
Estonian: elektrolüütide tasakaalu häired, hüperglükeemia, hüpokaltseemia, metaboolne atsidoos
English: 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion, not to exceed a final concentration of 0.5 mg/mL.
Estonian: Ringeri laktaadilahusele, mitte ületades lõplikku kontsentratsiooni 0,5 mg/ml.
English: Hepatobiliary disorders elevated liver enzyme levels (AST, ALT)
Estonian: Maksa ja sapiteede häired maksaensüümide (ASAT, ALAT) aktiivsuse suurenemine
English: There is no clinical experience in adult patients with severe hepatic impairment and in paediatric patients with any degree of hepatic impairment.
Estonian: Raske maksakahjustusega täiskasvanud patsientidel ja ükskõik millise raskusastme maksakahjustusega lastel puudub ravimi kasutamise kliiniline kogemus.
English: Caspofungin has been shown to cross the placental barrier in animal studies.
Estonian: Loomkatsetest on ilmnenud, et kaspofungiin läbib platsentaarbarjääri.
English: Preparation of the 50 mg/m2 infusion for paediatric patients >3 months of age (using a 50-mg vial)
Estonian: 50 mg/m2 infusioonilahuse valmistamine lastele vanuses > 3 kuu (kasutades 50 mg viaali)
English: Preparation of the 70 mg/m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial)
Estonian: 70 mg/m2 infusioonilahuse valmistamine lastele vanuses > 3 kuu (kasutades 70 mg viaali)
English: Renal and urinary disorders renal failure, renal failure acute
Estonian: Neerude ja kuseteede häired neerupuudulikkus, äge neerupuudulikkus
English: Preparation of the 70 mg/m2 infusion for paediatric patients >3 months of age (using a 50-mg vial)
Estonian: 70 mg/m2 infusioonilahuse valmistamine lastele vanuses > 3 kuu (kasutades 50 mg viaali)
English: In children (ages 2 to 11 years) receiving caspofungin at 50 mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg/day.
Estonian: 70 mg ööpäevas), oli kaspofungiini plasma AUC0-24hr korduvate annuste manustamise järgselt võrreldav 50 mg ööpäevas kaspofungiini saanud täiskasvanutega.
English: DATE OF REVISION OF THE TEXT
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED
English: Preparation of the 50 mg/m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial)
Estonian: 50 mg/m2 infusioonilahuse valmistamine lastele vanuses > 3 kuu (kasutades 70 mg viaali)
English: Breast-feeding
Estonian: Kaspofungiin
English: Musculoskeletal and connective tissue disorders arthralgia back pain, pain in extremity, bone pain, muscular weakness, myalgia
Estonian: Lihas-skeleti ja sidekoe kahjustused liigesevalu seljavalu, jäsemevalu, luuvalu, lihasnõrkus, lihasvalu
English: Reconstitution of Caspofungin Accord
Estonian: Caspofungin Accord'i lahustamine
English: Determine the actual daily maintenance dose to be used in the paediatric patient by using the patient's BSA (as calculated above) and the following equation:
Estonian: Määrake kindlaks tegelik ööpäevane säilitusannus lapspatsiendi jaoks, kasutades patsiendi kehapinna suurust (arvutatud ülaltoodud juhiste järgi) ja järgmist valemit: BSA (m2) X 50 mg/m2 = ööpäevane säilitusannus
English: For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are mandatory.
Estonian: Nende ravimite koosmanustamisel tuleb jälgida viimase plasmakontsentratsiooni ja vajadusel annust korrigeerida.
English: Cardiac disorders tachycardia
Estonian: Südame häired tahhükardia
English: Treatment should continue for 8 weeks.
Estonian: Ravi kestus on 8 nädalat.
English: What measures are being taken to ensure the safe and effective use of Oxervate?
Estonian: Mis meetmed võetakse, et tagada Oxervate ohutu ja efektiivne kasutamine?
English: Oxervate cenegermin
Estonian: Oxervate tsenegermiin
English: What is Oxervate and what is it used for?
Estonian: Mis on Oxervate ja milleks seda kasutatakse?
English: The recommended dose is 1 drop in the affected eye every 2 hours, 6 times per day.
Estonian: Soovitatav annus on 1 tilk haigesse silma iga 2 tunni järel 6 korda ööpäevas.
English: The European Medicines Agency therefore decided that Oxervate's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Oxervate kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Oxervate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Oxervate kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: It is not intended to provide practical advice on how to use Oxervate.
Estonian: Hindamisaruandes ei anta Oxervate kasutamise praktilisi nõuandeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oxervate have been included in the summary of product characteristics and the package leaflet.
Estonian: Oxervate ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: In the second study, figures were 70% (16 out of 23) with Oxervate and 29% (7 out of 24) with the dummy treatment.
Estonian: Teises uuringus olid vastavad näitajad Oxervate rühmas 70% (16 patsienti 23st) ja platseeborühmas 29% (7 patsienti 24st).
English: The full EPAR for Oxervate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Oxervate kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Oxervate has been shown to help heal damage to the eye's surface in 2 main studies involving a total of 204 adults with moderate or severe neurotrophic keratitis.
Estonian: Oxervate toimet silmapinna kahjustuste parandamisel tõendati kahes põhiuuringus, milles osales kokku 204 mõõduka või raske neurotroofse keratiidiga täiskasvanut.
English: The medicine is only used in adults with moderate or severe disease.
Estonian: Ravimit kasutatakse üksnes mõõduka või raske neurotroofse keratiidiga täiskasvanutel.
English: Other information about Oxervate
Estonian: Muu teave Oxervate kohta
English: What are the risks associated with Oxervate?
Estonian: Mis riskid Oxervatega kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Oxervate.
Estonian: See on ravimi Oxervate Euroopa avaliku hindamisaruande kokkuvõte.
English: Why is Oxervate approved?
Estonian: Miks Oxervate heaks kiideti?
English: The most common side effects with Oxervate (which may affect more than 1 in 100 people) are eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.
Estonian: Oxervate kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 100st) on silmavalu japõletik, suurenenud pisaravool, silmalau valulikkus ja tunne, et silmas on võõrkeha.
English: Side effects with Oxervate are mainly related to the eye, are mild or moderate in severity and resolve over time.
Estonian: Oxervate kõrvalnähud avalduvad peamiselt silmas, on kerged või mõõdukad ja taanduvad aja jooksul.
English: In the first study, 74% (37 out of 50) of patients treated with Oxervate for 8 weeks achieved complete healing of the eye's surface compared with 43% (22 out of 51) of patients treated with a dummy treatment containing the same eye drop formula but no active substance.
Estonian: Esimeses uuringus paranes Oxervatega 8 nädala jooksul ravitud patsientidest 74%-l (37 patsiendil 50st) silmapind täielikult, samas kui platseebot ehk näivat ravimit (samad silmatilgad, kuid ilma toimeaineta) saanud patsientide seas saavutas sama ravitulemuse 43% (22 patsienti 51st).
English: How is Oxervate used?
Estonian: Kuidas Oxervatet kasutatakse?
English: Patients with neurotrophic keratitis have lower than normal levels of substances including growth factors that are normally supplied by the trigeminal nerve and which play an important role in the growth and survival of the cells of the eye's surface.
Estonian: Neurotroofse keratiidiga patsientidel on silmapinnal normaalsest väiksem kogus aineid (sh kasvufaktoreid), mille tekkes tavaliselt osaleb kolmiknärv ning millel on oluline roll silmapinna rakkude kasvus ja ellujäämises.
English: For the full list of all side effects and restrictions with Oxervate, see the package leaflet.
Estonian: Oxervate kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: For practical information about using Oxervate, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Oxervate kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Oxervate has been shown to increase by around 30-40% the number of patients who achieve complete healing of the eye's surface when compared with eye drops containing no active substance.
Estonian: Uuringud näitasid, et silmapinna täieliku paranemise saavutanud patsientide arv oli Oxervate kasutamisel 30-40% võrra suurem kui toimeainet mittesisaldavate silmatilkade kasutamisel.
English: For more information about treatment with Oxervate, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Oxervatega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because the number of patients with neurotrophic keratitis is low, the disease is considered ‘rare', and Oxervate was designated an ‘orphan medicine' (a medicine used in rare diseases) on 14 December
Estonian: Et neurotroofse keratiidiga patsientide arv on väike ja see haigus esineb harva, nimetati Oxervate 14. detsembril 2015 harvikravimiks.
English: Oxervate contains the active substance cenegermin.
Estonian: Oxervate sisaldab toimeainena tsenegermiini.
English: What benefits of Oxervate have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Oxervate kasulikkus?
English: When given as eye drops to patients with neurotrophic keratitis, cenegermin helps restore some of the normal healing processes in the eye and repair damage to the eye's surface associated with the condition.
Estonian: Kui neurotroofse keratiidiga patsientidele manustatakse silmatilkadena tsenegermiini, aitab see taastada silmas teatud loomulikud paranemisprotsessid ning parandada haigusseisundist tingitud kahjustused silmapinnal.
English: The active substance in Oxervate, cenegermin, is a copy of a human growth factor called nerve growth factor.
Estonian: Oxervate toimeaine tsenegermiin on inimese närvikasvufaktori koopia.
English: How does Oxervate work?
Estonian: Kuidas Oxervate toimib?
English: Oxervate is available as eye drops.
Estonian: Oxervatet turustatakse silmatilkadena.
English: Oxervate can only be obtained with a prescription and treatment should be started and supervised by an eye specialist.
Estonian: Ravi peab alustama ning jälgima silmaarst.
English: Oxervate is a medicine used to treat neurotrophic keratitis, an eye condition in which damage to the trigeminal nerve supplying the surface of the eye causes loss of sensation and defects that do not heal naturally.
Estonian: Neurotroofne keratiit on silmahaigus, mille korral silmapinda läbiva kolmiknärvi kahjustus põhjustab tundlikkuse kadu ja kahjustusi, mis ei parane iseenesest.
English: This summary was last updated in 07-2017.
Estonian: Oxervate EMA/330858/2017
English: - The other ingredients are :
Estonian: - Teised koostisosad on:
English: Constella with food
Estonian: Constella koos toiduga
English: Do not swallow them.
Estonian: Ärge neid alla neelake.
English: Just take the next dose at the scheduled time and continue as normal.
Estonian: Võtke lihtsalt järgmine annus ettenähtud ajal ja jätkake tavapärase skeemi järgi.
English: These symptoms may vary from person to person.
Estonian: Need sümptomid võivad inimestel erineda.
English: After first opening: 18 weeks.
Estonian: Pärast esmast avamist: 18 nädalat.
English: However, treatment with Constella can be safely stopped at any time.
Estonian: Siiski võib ravi Constellaga mis tahes ajal ohutult lõpetada.
English: Physicians should periodically assess the need for continued treatment.
Estonian: Arstid peavad ravi jätkamise vajadust perioodiliselt hindama.
English: The active metabolite was not detected in any of the 162 patients at any time point.
Estonian: Aktiivset metaboliiti ei tuvastatud ühelgi ajaperioodil ühelgi patsiendil 162-st.
English: The safety and efficacy of Constella in children aged 0 to18 years have not yet been established.
Estonian: Constella ohutus ja efektiivsus lastel vanuses 0 kuni 18 aastat ei ole veel tõestatud.
English: Component of a multipack, can't be sold separately.
Estonian: Multipaki osa, mida ei saa eraldi müüa.
English: Placebo (N =797)
Estonian: Platseebo (N = 797)
English: Linaclotide (N =805)
Estonian: Linaklotiid (N = 805)
English: Do not take this medicine if you are pregnant, think you may be pregnant or are planning to have a baby, unless your doctor advises you to do so.
Estonian: Ärge võtke seda ravimit, kui te olete rase, arvate end olevat rase või kavatsete rasestuda, välja arvatud juhul, kui teie arst seda soovitab.
English: Unopened bottle for 10 capsules: 2 years.
Estonian: Avamata pudel, milles on 10 kapslit: 2 aastat.
English: For age related information, please see sections 4.2., 4.4., and 4.8.
Estonian: Vanust puudutava teabe saamiseks vt lõike 4.2, 4.4 ja 4.8.
English: Because these other diseases may have the same symptoms as IBS, it is important that you report any change or irregularity in symptoms to your doctor promptly.
Estonian: Kuna teistel haigustel võivad olla samasugused sümptomid kui soole ärritussündroomil, on oluline, et teavitaksite arsti viivitamatult mis tahes muudatustest sümptomites või nende ebaregulaarsusest.
English: LS: Least Square CSBM: Complete Spontaneous Bowel Movement
Estonian: LS: vähimruut CSBM: täielik spontaanne defekatsioon
English: As a precautionary measure, it is preferable to avoid the use of Constella during pregnancy.
Estonian: Ettevaatusena on parem vältida Constella kasutamist raseduse ajal.
English: The capsule should be taken at least 30 minutes before a meal.
Estonian: Kapsel tuleb võtta vähemalt 30 minutit enne sööki.
English: Total exposure in the clinical development plan exceeded 1,500 patient-years.
Estonian: Summaarne ravimiga kokkupuude kliinilises programmis ületas 1500 patsientaastat.
English: Do not give this medicine to children and adolescents under the age of 18 years because the safety and efficacy of Constella in this age group has not been established.
Estonian: Ärge andke seda ravimit lastele ja alla 18-aastastele noorukitele, kuna Constella ohutus ja efektiivsus selles vanusegrupis pole tõestatud.
English: Do not use this medicine if you notice any signs of damage to the bottle or any change in the appearance of the capsules.
Estonian: Ärge kasutage seda ravimit, kui täheldate pudelil kahjustust või mis tahes muutust kapslite välimuses.
English: Side effects with frequency not known (frequency cannot be estimated from the available data):
Estonian: Teadmata esinemissagedusega kõrvaltoimed (esinemissagedust ei saa hinnata olemasolevate andmete alusel)
English: Date of first authorisation: 26 November 2012 Date of latest renewal: 28 August 2017
Estonian: Müügiloa viimase uuendamise kuupäev: 28. august 2017
English: If you stop taking Constella
Estonian: Kui te lõpetate Constella võtmise
English: What you need to know before you take Constella 3.
Estonian: Mida on vaja teada enne Constella võtmist
English: This medicinal product should not be used in children and adolescents (see sections 4.4 and 5.1).
Estonian: Seda ravimit ei soovitata kasutada lastel ja noorukitel (vt lõigud 4.4 ja 5.1).
English: In the second clinical study (study 2), 800 patients were treated for 12 weeks, and then re-randomised for an additional 4 weeks treatment period.
Estonian: Teises kliinilises uuringus (uuring 2) raviti 800 patsienti 12 nädalat ja seejärel randomiseeriti uuesti täiendavaks 4-nädalaseks raviperioodiks.
English: As GC-C receptor is known to be overexpressed at early ages, children younger than 2 years may be particularly sensitive to linaclotide effects.
Estonian: Kuna esimestel eluaastatel esineb teadaolevalt guanülaattsüklaas-C (GC-C) retseptorite ülemäärane aktiivsus, võivad alla 2-aastased lapsed olla linaklotiidi toimete suhtes eriti tundlikud.
English: CSBM/week
Estonian: CSBM-i/nädalas 0,2
English: MedDRA system organ class
Estonian: MedDRA organsüsteemi klass Väga sage Sage
English: Once the bottle is opened, the capsules should be used within 18-weeks.
Estonian: Pärast pudeli avamist tuleb kapslid ära kasutada 18 nädala jooksul.
English: Patients with known or suspected mechanical gastrointestinal obstruction.
Estonian: Teadaoleva või kahtlustatava seedetrakti mehaanilise obstruktsiooniga patsiendid.
English: If patients have not experienced improvement in their symptoms after 4 weeks of treatment, the patient should be re-examined and the benefit and risks of continuing treatment reconsidered.
Estonian: Kui patsientidel ei ole sümptomid pärast 4-nädalast ravi paranenud, tuleb patsient uuesti läbi vaadata ning hinnata ravi jätkamise eeliseid ja riske.
English: Constella should not be used in children and adolescents as it has not been studied in this population.
Estonian: Constellat ei tohi lastel ja noorukitel kasutada, kuna seda ei ole selles populatsioonis uuritud.
English: It is expected that linaclotide is negligibly or not systemically distributed.
Estonian: Eeldatavasti jaotub linaklotiid süsteemselt ebaolulisel hulgal või üldse mitte.
English: • infrequent, hard, small or pellet-like stools (faeces).
Estonian: • harvad kõvad väikesed või pabulataolised väljaheited (faeces).
English: Approximately half of the diarrhoea episodes started within the first week of treatment.
Estonian: Ligikaudu pooled kõhulahtisuse episoodidest algas esimese ravinädala jooksul.